Patient-derived organoids and mini-PDX for predicting METN375S-mutated lung cancer patient clinical therapeutic response
Lung cancer as a molecularly and histologically high heterogonous disease, there is an urgent need to predict lung cancer patients' responses to anti-cancer treatment, and patient-derived organoids (PDOs) have been recognized as a valuable platform for preclinical drug screening. In this study,...
| المؤلفون الرئيسيون: | , , , , , , , , , , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
Elsevier
2024-09-01
|
| سلاسل: | Heliyon |
| الوصول للمادة أونلاين: | http://www.sciencedirect.com/science/article/pii/S2405844024139151 |